Rarecells Diagnostics SAS
Rarecells Diagnostics SAS, headquartered in France, is a pioneering company in the field of liquid biopsy and cancer diagnostics. Founded in 2014, Rarecells has established itself as a leader in the development of innovative technologies for the isolation and analysis of circulating tumour cells (CTCs), which are crucial for early cancer detection and personalised treatment strategies. With a focus on enhancing patient outcomes, Rarecells offers unique products such as the Rarecells CTC isolation platform, which stands out for its high sensitivity and specificity. The company operates primarily in Europe and has made significant strides in advancing cancer diagnostics, contributing to its strong market position. Rarecells Diagnostics continues to push the boundaries of cancer research, making notable achievements in the realm of precision medicine.
DitchCarbon Score
How does Rarecells Diagnostics SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Rarecells Diagnostics SAS's score of 6 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Rarecells Diagnostics SAS's reported carbon emissions
Rarecells Diagnostics SAS, headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Rarecells Diagnostics SAS may still be in the early stages of developing a comprehensive sustainability strategy. As the company operates within the diagnostics industry, it is essential for them to consider establishing measurable climate goals and reporting frameworks to align with industry standards and expectations. Engaging with initiatives such as the Science Based Targets initiative (SBTi) could provide a structured approach to setting and achieving future emissions reduction targets. In summary, Rarecells Diagnostics SAS has not yet disclosed any emissions data or climate commitments, highlighting an opportunity for the company to enhance its environmental accountability and sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Rarecells Diagnostics SAS is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
